Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
- 1 February 2014
- journal article
- review article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 103 (2) , 269-275
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company
- AstraZeneca
- Novo Nordisk
- Merck
- Bristol-Myers Squibb
- Eli Lilly and Company
- Sanofi
This publication has 15 references indexed in Scilit:
- GLP-1 receptor agonists: A clinical perspective on cardiovascular effectsDiabetes & Vascular Disease Research, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studiesDiabetes & Vascular Disease Research, 2011
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical TrialsExperimental Diabetes Research, 2011
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or SitagliptinDiabetes Care, 2010
- Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and BenefitsDiabetes Care, 2010
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburideCurrent Medical Research and Opinion, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996